The Pharmacy Times® Immuno-oncology Resource Center is a comprehensive resource for clinical news and expert insights on treatments that harness the body's immune system to fight cancer.
October 17th 2024
Compared with brentuximab vedotin and chemotherapy, nivolumab and chemotherapy had longer progression-free survival and a better safety profile.
Chronic Myeloid Leukemia: Navigating Drug Resistance and Optimizing Care
1.0 Credit / Hematologic Cancer, Hematology, Oncology
View More
Emerging Trends in the Use of FGFR Inhibitors for Advanced Cholangiocarcinoma Treatment
1.0 Credits / Oncology
View More
Balancing Anticancer Efficacy and Cardiovascular Safety: A Pharmacist's Guide
1.0 Credits / Oncology
View More
Balancing the Benefits and Risks of Asparaginase Treatment in Adults and Young Adults With Acute Lymphoblastic...
1.0 Credits / Oncology
View More
Maximizing Efficacy and Minimizing Toxicity of CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer
1.0 Credits / Oncology
View More
Optimizing Use of Small Molecule Inhibitors in Chronic Lymphocytic Leukemia: Strategies for Safe and Effective...
1.0 Credits / Hematology, Oncology
View More
Recognizing the Signs and Symptoms of Cytokine Release Syndrome in Novel Cancer Therapies: Strategies for Onco...
1.0 Credits / Oncology
View More
PARP Inhibitors for Ovarian Cancer: An Oncology Pharmacist's Guide to the Latest Clinical Advancements
1.0 Credits / Oncology
View More
Revolutionizing the Treatment of Endometrial Cancer by Leveraging the Potential of Immune Checkpoint Inhibitor...
1.0 Credits / Oncology
View More
Navigating the Evolving Treatment Landscape of Metastatic Renal Cell Carcinoma
2.0 Credits / Nephrology, Oncology
View More
Advances in the Treatment of Metastatic Renal Cell Carcinoma: New Horizons in Targeted Therapies
1.0 Credit / Genitourinary Cancer, Oncology
View More
Optimizing Asparaginase Use in Acute Lymphoblastic Leukemia: A Comprehensive Program on Safety and Efficacy
1.0 Credit / Genitourinary Cancer, Oncology
View More
Navigating Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatment: An Interdisciplinary Approach
1.5 Credits / Oncology
View More
Mastering Oncology Clinical Trials: Immune Checkpoint Inhibitors in Frontline Metastatic Non–Small Cell Lung C...
1.5 Credits / Lung Cancer, Oncology
View More
Navigating the Evolving Landscape of HER2-Positive Early-Stage Breast Cancer: Considerations for Managed Care
2.0 Credits / Breast Cancer, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Recent Advances in BCMA-Directed Treatment in Multiple Myeloma: Insights and Application for Managed Care
1.0 Credits / Hematologic Cancer, Oncology
View More
Revolutionizing Multiple Myeloma Care: CAR T-Cell Therapy, Bispecific Antibodies, and Patient-Centered Strateg...
1.0 Credit / Oncology, Hematologic Cancer
View More
Managed Care Approaches to Improve Outcomes in Frontline Therapy for Renal Cell Carcinoma
2.0 Credits / Oncology
View More
Challenges in Treatment of Desmoid Tumors and Managed Care Solutions
0.5 Credit / Oncology
View More
Desmoid Tumors: What Managed Care Professionals Need to Know to Manage These Unpredictable Tumors, featuring a...
2.0 Credits / Oncology
View More
Optimizing Bispecific Antibody Utilization in Non-Hodgkin Lymphoma: Addressing Challenges in Community-Based C...
1.0 Credit / Hematologic Cancer, Oncology
View More
Elevating Safety and Adherence in Chronic Myeloid Leukemia Through Oncology Pharmacist Expertise
1.0 Credit / Hematologic Cancer, Oncology
View More
Optimizing JAK Inhibitor Therapy for Myelofibrosis: Insights for Oncology Pharmacists
1.0 Credit / Hematologic Cancer, Oncology
View More
Advancements in Early-Stage Breast Cancer: The Role of Oncology Pharmacists in Treatment Optimization
1.0 Credit / Breast Cancer, Women’s Health, Oncology
View More
Balancing Innovation and Implementation: A Comprehensive Approach to CAR T, Bispecific Antibodies, and Operati...
1.0 Credit / Hematologic Cancer, Oncology
View More
Precision Oncology in Practice: Transforming Non–Small Cell Lung Cancer Care Through Advanced Biomarker Testin...
0.75 Credit / Oncology
View More
Finding Balance Between Advancement and Application: A Guide for Community Oncology Pharmacists on CAR T-Cell ...
0.75 Credit / Oncology, Hematologic Cancer
View More
Ensuring the Safe, Effective, and Equitable Care of Patients With Advanced Endometrial Cancer: Strategies for ...
0.75 Credit / Oncology
View More
Navigating the Use of Bispecific Antibodies in Non-Hodgkin Lymphoma: Solutions to Enhance Community-Based Care
0.75 Credit / Oncology
View More
Clinical research presented at ESMO 2024 highlights the significant survival benefits of perioperative and neoadjuvant immunotherapy with nivolumab and nivolumab plus ipilimumab, while emphasizing the role of biomarkers such as ctDNA and KRAS mutations in guiding treatment decisions.
Read More
An ESMO 2024 presentation explores the growing role of the gut microbiome in immunotherapy response, emerging diagnostic tools such as PCR chips, and innovative therapies such as fecal microbiota transplantation and microbiome-preserving strategies to improve patient outcomes.
Read More
FDA Approves Pembrolizumab Resectable Non–Small Cell Lung Cancer
October 17th 2023Pembrolizumab (Keytruda) gains its sixth approval in non–small cell lung cancer (NSCLC), with the latest indication in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a monotherapy for the post-surgical adjuvant treatment of patients with resectable NSCLC.
Read More
Enfortumab Vedotin-ejfv, Pembrolizumab Combination Shows Promise Treating Urothelial Cancer
September 26th 2023Investigators reported that enfortumab vedotin-ejfv (Padcev; Astella Pharma Inc, Seagen Inc) in combination with pembrolizumab (Keytruda; Merck & Co Inc) met the dual primary endpoints of overall survival and progression-free survival in patients with previously untreated locally advanced or metastatic urothelial cancer.
Read More
Axicabtagene Ciloleucel Demonstrates High Response Rate in Relapsed/Refractory Large B-cell Lymphoma
September 22nd 2023Axicabtagene ciloleucel achieved a complete metabolic response of 71% at 3 months versus 12% expected with standard of care among transplant ineligible patients with relapsed/refractory large B-cell lymphoma.
Read More
Study Suggests Base-Edited T Cells Could Minimize Immunotherapy Complications in Leukemia Treatment
September 14th 2023The use of base editing to generate universal, off-the-shelf CAR T cells is a promising approach for relapsed leukemia, with potential implications for the future of gene therapy.
Read More